The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women

Journal of the American Geriatrics Society

Volumn 44, Issue 7, 1996, Pages 818-822

  Paganini Hill, Annlia ^a,b   Henderson, Victor W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CHOLESTEROL; ESTRADIOL; ESTROGEN; ESTRONE; GESTAGEN; HORMONE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARACETAMOL; PROGESTERONE;

AGED; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; DEMENTIA; DRUG USE; ESTROGEN THERAPY; FEMALE; HEALTH SURVEY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; TASK PERFORMANCE;

EID: 0030001219     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1996.tb03740.x     Document Type: Article

References (39)

1. Shulman K, Shedletsky R, Silver IL. The challenge of time: Clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1986;1:135-140.
2. Sunderland T, Hill JL, Mellow AM et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989;37:725-729.
3. Wolf-Klein GP, Silverstone FA, Levy AP et al. Screening for Alzheimer's disease by clock drawing. J Am Geriatr Soc 1989;37:730-734.
4. Dastoor DP, Schwartz G, Kurzman D. Clock-drawing - An assessment technique in dementia. J Clin Exp Gerontol 1991;13:69-85.
5. Rouleau I, Salmon DP, Butters N et al. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
6. Tuokko H, Hadjistavropoulos T, Miller JA, Beattie BL. The clock test: A sensitive measure to differentiate normal elderly from those with Alzheimer's disease. J Am Geriatr Soc 1991;40:579-584.
7. Mendez MF, Ala T, Underwood KL. Development of scoring criteria for the clock drawing task in Alzheimer's disease. J Am Geriatr Soc 1992;40:1095-1099.
8. Logan CG, Buckwalter JC, Henderson VW. Clock drawing in Alzheimer's disease. Soc Neurosci Abstr 1993;19:187.
9. Shulman KI, Gold DP, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: A longitudinal study. Int J Geriatr Psychiatry 1993;8:487-496.
10. Watson YI, Arfken CL, Birge SL. Clock completion: An objective screening test for dementia. J Am Geriatr Soc 1993;41:1235-1240.
11. Freedman M, Leach L, Kaplan et al. Clock Drawing: A Neuropsychological Analysis. New York: Oxford University Press, 1994.
12. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-261.
13. Henderson VW, Paganini-Hill A, Emanuel CK et al. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
14. Fillit H, Weinreb H, Cholst I et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-345.
15. Honjo H, Ogino Y, Tanaka K et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double blind study. J Jpn Menopause Soc 1993;1:167-171.
16. Ohkura T, Isse K, Akazawa K et al. Evaluation of estrogen treatment in female patients with dementia of Alzheimer type. Endocr J 1994;41:361-371.
17. Ohkura T, Isse K, Akazawa K et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6:99-107.
18. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: A cohort study of the elderly. Br Med J 1989;299:1247-1250.
19. Paganini-Hill A, Dworsky R, Krauss RM. Hormone replacement therapy, hormone levels and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol, 1996;174:897-902.
20. Katzman R, Brown T, Fuld P et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1981;140:734-739.
21. Barrett-Connor E, Krite-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-2641.
22. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women: I. Results of therapy after six months. J Gerontol 1952;7:228-244.
23. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-357.
24. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
25. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83:979-983.
26. Hampson E. Estrogen-related variations in human spatial and articulatory-motor skills. Psychoneuroendocrinology 1990;15:97-111.
27. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: Impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: Physiology and Pharmacology. Chicago: YearBook Medical Publishers, 1987, pp 187-208.
28. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
29. Meldrum DR, Davidson BJ, Tataryn IV et al. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981;57:624-628.
30. Berlinger WG, Potter JF. Low body mass index in demented outpatients. J Am Geriatr Soc 1991;39:973-978.
31. Buckwalter JG, Schneider LS, Dunn ME, Henderson VW. Tacrine Study Group. Higher body weight is associated with better cognitive performance in women with probable Alzheimer's disease. Neurology (abstract)1994;44(suppl):187.
32. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
33. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
34. Heyman A, Wilkinson WE, Stafford JA et al. Alzheimer's disease: A study of epidemiological aspects. Ann Neurol 1984;15:335-341.
35. Amaducci LA, Fratiglioni L, Rocca WA et al. Risk factors for clinically diagnosed Alzheimer's disease: A case-control study of an Italian population. Neurology 1986;36:922-931.
36. Graves AB, White E, Koepsell TD et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
37. Broe GA, Henderson AS, Creasey H et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-1707.
38. Henderson AS, Jorm AF, Korten AE et al. Environmental risk factors for Alzheimer's disease: Their relationship to age of onset and to familial or sporadic types. Psychol Med 1992;22:429-436.
39. Breitner JCS, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994;44:227-232.